Abstract
Though chemotherapy is the major strategy to manage patients with advanced-stage colorectal cancer (CRC), the main challenge is the progression of CRC despite using combination of different chemotherapeutic agents. So, to overcome this challenge, a new class
 Of therapy was developed naming “Targeted-therapy”. This class of drugs aim to target specific overexpressed or aberrant enzyme, receptor, or gene that have critical role in the growth and survival of colorectal cancerous cells. So that, by using combination of traditional strategy (chemotherapy) and targeted-drug, this will lead to improve survival and prevent the progression of advanced CRC
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Al Mustansiriyah Journal of Pharmaceutical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.